Christina Jones
Addiction Medicine · Sulphur, LANPI 1184754723
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,165 of the $43,807 with a category attached, or 66.6%. 22 manufacturers reported payments, led by Gilead at 54.8% of the total. 2025 is the largest year on record at $40,698, more than ten times the $480 reported in 2019. Among addiction medicine clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $169.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$24K
- Indivior Inc.$16K
- AbbVie$705
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$594
- Alkermes, Inc.$370
- Vanda Pharmaceuticals Inc.$322
- plus $1K from 16 others
What the payments were for
- Speaking & faculty fees$29,16567%
- Travel & lodging$8,86720%
- Food & beverage$5,73313%
- Education$120%
- Gifts$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 33 | $24,019 |
| Indivior Inc. | 56 | $16,405 |
| AbbVie | 48 | $705 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $594 |
| Alkermes, Inc. | 11 | $370 |
| Vanda Pharmaceuticals Inc. | 18 | $322 |
| Teva Pharmaceuticals USA, Inc. | 21 | $287 |
| Sunovion Pharmaceuticals Inc. | 9 | $245 |
| Axsome Therapeutics, Inc. | 5 | $192 |
| Neurocrine Biosciences, Inc. | 9 | $179 |
| Otsuka America Pharmaceutical, Inc. | 4 | $77 |
| Braeburn Inc. | 4 | $69 |
| Eisai Inc. | 5 | $65 |
| Johnson & Johnson | 3 | $62 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Avanir Pharmaceuticals, Inc. | 2 | $35 |
| Supernus Pharmaceuticals, Inc. | 2 | $33 |
| Merz North America, Inc. | 1 | $30 |
| Noven Therapeutics, LLC | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Rhodes Pharmaceuticals L.p. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,807 in reported general payments places this provider in the 90th percentile of 28 addiction medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 97 | $22,456 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 19 | $16,460 |
| QuviviqDaridorexant Hcl | 11 | $5,649 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,356 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 12 | $651 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 20 | $647 |
| Buprenorphine Hcl | 12 | $519 |
| Olanzapine | 11 | $450 |
| Gabapentin | 36 | $429 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $321 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 14 | $105 |
| Clonidine Hcl | 22 | $81 |
| Amitriptyline Hcl | 12 | $81 |
| Quetiapine Fumarate | 21 | $69 |
| Ondansetron Hcl | 12 | $46 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $18 | $5,35611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 28 addiction medicine providers in Louisiana.
Other addiction medicine in Sulphur
- Susan JuliusBaton Rouge$255K
- Richard SipesShreveport$56K
- Kirit PatelShreveport$37K
- Alphonse RoyMetairie$23K
- Philip IsherwoodShreveport$4K
- Indira KailasMarrero$3K
- James ChivertonMetairie$2K
- Anthony PeperoneMandeville$2K
- Brandie SmithCovington$1K
- Smita PrasadNew Orleans$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.